Clinical Trial Search

Primary: Progression-free Survival at 6 Months — 40.3 percentage of participants

Primary: Four Cycle Progression-free Survival Rate — 8 Participants

Primary: Efficacy: Progression-free Survival (PFS) — 4.3; 2.8; 5.3; 2.8 Months — p=0.0220

Primary: Tumor Response — 7; 30; 12; 6 participants

Primary: Median Time to Progression — 7.2 months

Primary: Patients' Overall 90-Day Clinical Response as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) — 8; 18 Participants

Primary: Proportion of Patients With Complete and Partial Tumor Response — 0.26 Proportion of patients

Primary: Phase 1b: Recommended Phase 2 Dose of LY2228820 in Combination With Gemcitabine and Carboplatin (Maximum Tolerated Dose [MTD]) — 200 milligrams (mg)

Primary: Objective Tumor Response — 4; 8; 8; 32 Participants

Primary: Progression Free Survival (PFS) Rate at 6 Months — 55.2 percentage of patients

Primary: Objective Response to Treatment With Eribulin Mesylate in Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer. — 2; 7; 16; 21 participants

Primary: Progression-free Survival Rate After 6 Months of Treatment on Study — 0 participants

Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.1 — 0; 1 participants

Primary: Tumor Response Duration — 3.9; 24.1 months

Primary: Objective Response (Partial Response or Complete Response) as Per the Response Evaluation Criteria in Solid Tumors (RECIST) Criteria — 3.6 percentage of evalubale patients

Primary: Patients Who Survive Progression-free for at Least 6 Months — 6; 14 Participants

Primary: Objective Tumor Response — 21; 32; 17; 1 participants

Primary: Progression-free Survival — 5.9; 4.5 months

Primary: Progression-free Survival (PFS) > 6 Months — 8.0 percentage of participants

Primary: Percentage of Patients Alive and Progression Free Survival at 12 Weeks — 47 percentage of patients

Primary: Percentage of Participants With Progression-Free Survival at 6 Months (PFS-6) — 25.0 percentage of participants

Primary: 6 Month Progression-free Survival (PFS) — 13 participants

Primary: Objective Response Rate (ORR) — 2; 0 Participants

Primary: Objective Tumor Response — 12.2; 31.4 percentage of participants

Primary: Overall Response — 1; 1 Participants

Primary: Progression-free Survival (PFS) — 56 percentage of participants

Primary: Overall Response Rate (ORR) — 4 participants

Primary: Number of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 2; 0 Participants

Primary: Tumor Response — 14.3 percentage of participants

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants